ARTICLE | Finance
HepaRegeniX aims to bring liver program into clinic with €11M insider round
Existing investors back German academic spinout as its first-in-class molecule nears the clinic
January 22, 2020 7:23 PM UTC
With €11 million ($12.2 million) in fresh series B funding from insiders, liver regeneration company HepaRegeniX hopes to have a first-in-class molecule in the clinic by fall 2020.
Participating in the round were Boehringer Ingelheim Venture Fund, Novo Holdings A/S, High-Tech Gründerfonds, Coparion GmbH & Co. and Ascenion GmbH. The group had supplied €9 million in a series A round closed in January 2017...
BCIQ Company Profiles
BCIQ Target Profiles